Novel serine 176 phosphorylation of YBX1 activates NF-κB in colon cancer

Matthew Martin, Laiqing Hua, Benlian Wang, Han Wei, Lakshmi Prabhu, Antja Voy Hartley, Guanglong Jiang, Yunlong Liu, Tao Lu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Y box protein 1 (YBX1) is a well known oncoprotein that has tumor-promoting functions. YBX1 is widely considered to be an attractive therapeutic target in cancer. To develop novel therapeutics to target YBX1, it is of great importance to understand how YBX1 is finely regulated in cancer. Previously, we have shown that YBX1 could function as a tumor promoter through phosphorylation of its Ser-165 residue, leading to the activation of the NF-κB signaling pathway (1). In this study, using mass spectrometry analysis, we discovered a distinct phosphorylation site, Ser-176, on YBX1. Overexpression of the YBX1-S176A (serine-to-alanine) mutant in either HEK293 cells or colon cancer HT29 cells showed dramatically reduced NF-κB-activating ability compared with that of WT-YBX1, confirming that Ser-176 phosphorylation is critical for the activation of NF-κB by YBX1. Importantly, the mutant of Ser-176 and the previously reported Ser-165 sites regulate distinct groups of NF-κB target genes, suggesting the unique and irreplaceable function of each of these two phosphorylated serine residues. Our important findings could provide a novel cancer therapy strategy by blocking either Ser-176 or Ser-165 phosphorylation or both of YBX1 in colon cancer.

Original languageEnglish (US)
Pages (from-to)3433-3444
Number of pages12
JournalJournal of Biological Chemistry
Volume292
Issue number8
DOIs
StatePublished - Feb 24 2017

Fingerprint

Y-Box-Binding Protein 1
Phosphorylation
Colonic Neoplasms
Serine
Neoplasms
Chemical activation
HT29 Cells
HEK293 Cells
Oncogene Proteins
Alanine
Carcinogens
Mass spectrometry
Tumors
Mass Spectrometry

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Novel serine 176 phosphorylation of YBX1 activates NF-κB in colon cancer. / Martin, Matthew; Hua, Laiqing; Wang, Benlian; Wei, Han; Prabhu, Lakshmi; Hartley, Antja Voy; Jiang, Guanglong; Liu, Yunlong; Lu, Tao.

In: Journal of Biological Chemistry, Vol. 292, No. 8, 24.02.2017, p. 3433-3444.

Research output: Contribution to journalArticle

Martin, M, Hua, L, Wang, B, Wei, H, Prabhu, L, Hartley, AV, Jiang, G, Liu, Y & Lu, T 2017, 'Novel serine 176 phosphorylation of YBX1 activates NF-κB in colon cancer', Journal of Biological Chemistry, vol. 292, no. 8, pp. 3433-3444. https://doi.org/10.1074/jbc.M116.740258
Martin, Matthew ; Hua, Laiqing ; Wang, Benlian ; Wei, Han ; Prabhu, Lakshmi ; Hartley, Antja Voy ; Jiang, Guanglong ; Liu, Yunlong ; Lu, Tao. / Novel serine 176 phosphorylation of YBX1 activates NF-κB in colon cancer. In: Journal of Biological Chemistry. 2017 ; Vol. 292, No. 8. pp. 3433-3444.
@article{be74583364c24680a215b039b32973ff,
title = "Novel serine 176 phosphorylation of YBX1 activates NF-κB in colon cancer",
abstract = "Y box protein 1 (YBX1) is a well known oncoprotein that has tumor-promoting functions. YBX1 is widely considered to be an attractive therapeutic target in cancer. To develop novel therapeutics to target YBX1, it is of great importance to understand how YBX1 is finely regulated in cancer. Previously, we have shown that YBX1 could function as a tumor promoter through phosphorylation of its Ser-165 residue, leading to the activation of the NF-κB signaling pathway (1). In this study, using mass spectrometry analysis, we discovered a distinct phosphorylation site, Ser-176, on YBX1. Overexpression of the YBX1-S176A (serine-to-alanine) mutant in either HEK293 cells or colon cancer HT29 cells showed dramatically reduced NF-κB-activating ability compared with that of WT-YBX1, confirming that Ser-176 phosphorylation is critical for the activation of NF-κB by YBX1. Importantly, the mutant of Ser-176 and the previously reported Ser-165 sites regulate distinct groups of NF-κB target genes, suggesting the unique and irreplaceable function of each of these two phosphorylated serine residues. Our important findings could provide a novel cancer therapy strategy by blocking either Ser-176 or Ser-165 phosphorylation or both of YBX1 in colon cancer.",
author = "Matthew Martin and Laiqing Hua and Benlian Wang and Han Wei and Lakshmi Prabhu and Hartley, {Antja Voy} and Guanglong Jiang and Yunlong Liu and Tao Lu",
year = "2017",
month = "2",
day = "24",
doi = "10.1074/jbc.M116.740258",
language = "English (US)",
volume = "292",
pages = "3433--3444",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "8",

}

TY - JOUR

T1 - Novel serine 176 phosphorylation of YBX1 activates NF-κB in colon cancer

AU - Martin, Matthew

AU - Hua, Laiqing

AU - Wang, Benlian

AU - Wei, Han

AU - Prabhu, Lakshmi

AU - Hartley, Antja Voy

AU - Jiang, Guanglong

AU - Liu, Yunlong

AU - Lu, Tao

PY - 2017/2/24

Y1 - 2017/2/24

N2 - Y box protein 1 (YBX1) is a well known oncoprotein that has tumor-promoting functions. YBX1 is widely considered to be an attractive therapeutic target in cancer. To develop novel therapeutics to target YBX1, it is of great importance to understand how YBX1 is finely regulated in cancer. Previously, we have shown that YBX1 could function as a tumor promoter through phosphorylation of its Ser-165 residue, leading to the activation of the NF-κB signaling pathway (1). In this study, using mass spectrometry analysis, we discovered a distinct phosphorylation site, Ser-176, on YBX1. Overexpression of the YBX1-S176A (serine-to-alanine) mutant in either HEK293 cells or colon cancer HT29 cells showed dramatically reduced NF-κB-activating ability compared with that of WT-YBX1, confirming that Ser-176 phosphorylation is critical for the activation of NF-κB by YBX1. Importantly, the mutant of Ser-176 and the previously reported Ser-165 sites regulate distinct groups of NF-κB target genes, suggesting the unique and irreplaceable function of each of these two phosphorylated serine residues. Our important findings could provide a novel cancer therapy strategy by blocking either Ser-176 or Ser-165 phosphorylation or both of YBX1 in colon cancer.

AB - Y box protein 1 (YBX1) is a well known oncoprotein that has tumor-promoting functions. YBX1 is widely considered to be an attractive therapeutic target in cancer. To develop novel therapeutics to target YBX1, it is of great importance to understand how YBX1 is finely regulated in cancer. Previously, we have shown that YBX1 could function as a tumor promoter through phosphorylation of its Ser-165 residue, leading to the activation of the NF-κB signaling pathway (1). In this study, using mass spectrometry analysis, we discovered a distinct phosphorylation site, Ser-176, on YBX1. Overexpression of the YBX1-S176A (serine-to-alanine) mutant in either HEK293 cells or colon cancer HT29 cells showed dramatically reduced NF-κB-activating ability compared with that of WT-YBX1, confirming that Ser-176 phosphorylation is critical for the activation of NF-κB by YBX1. Importantly, the mutant of Ser-176 and the previously reported Ser-165 sites regulate distinct groups of NF-κB target genes, suggesting the unique and irreplaceable function of each of these two phosphorylated serine residues. Our important findings could provide a novel cancer therapy strategy by blocking either Ser-176 or Ser-165 phosphorylation or both of YBX1 in colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=85013816476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013816476&partnerID=8YFLogxK

U2 - 10.1074/jbc.M116.740258

DO - 10.1074/jbc.M116.740258

M3 - Article

C2 - 28077578

AN - SCOPUS:85013816476

VL - 292

SP - 3433

EP - 3444

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 8

ER -